Skip to main content

Table 4 Univariate and multivariate analysis for OS and PFS in the study cohort

From: Primary breast double-hit lymphoma management and outcomes: a real-world multicentre experience

Factors Univariate analysis Multivariate analysis
OS PFS OS PFS
HR 95% CI P-value HR 95% CI P-value HR 95% CI P-value HR 95% CI P-value
Age
≤ 50 years 1.0 0.5–2.1 0.965 0.9 0.4–1.9 0.845       
 50–60 years             
Laterality        
 Left 0.3 0.1–0.7 0.005 0.3 0.1–0.6 0.003 3.580 0.475-26.969 0.216 2.215 0.326–15.045 0.416
 Right 0.2 0.1–0.6 0.003 0.2 0.1–0.6 0.004 0.848 0.170–4.230 0.840 0.673 0.142–3.198 0.618
 Bilateral             
Tumor size
 ≥ 5 cm 2.3 1.1–4.9 0.030 2.3 1.1–4.8 0.022 4.771 1.624–14.020 0.004 4.517 1.643–12.416 0.003
 < 5 cm             
Cell of origin          
 GCB 1.1 0.4- 3.0 0.776 1.2 0.5–3.1 0.712       
 Non-GCB             
Results of FISH          
 MYC-BCL2 0.5 0.2–1.2 0.114 0.6 0.3–1.3 0.199       
 MYC-BCL6             
BCL2 of IHC        
 BCL2 + 1.3 0.2–9.4 0.809 1.4 0.2–10.3 0.743       
BCL6 of IHC
 BCL2 = 6 + 0.9 0.2–3.7 0.862 1.0 0.2–4.2 0.991       
CD5 of IHC  
 CD5 + 1.8 0.8–3.7 0.144 1.6 0.7–3.2 0.240       
CD10 of IHC     
 CD10 + 1.1 0.5–2.4 0.759 1.1 0.5–2.3 0.785       
P53 of IHC   
 P53 + 1.4 0.6–3.3 0.452 1.6 0.7–3.7 0.295       
Ann Arbor staging         
 IE 0.1 0-0.4 0.001 0.1 0-0.5 0.001 1.4 0.1–21.7 0.801 5.3 0. 4-68.7 0.203
 IIE 0.3 0.2–0.8 0.010 0.4 0.2–0.8 0.009 0.9 0.1–8.2 0.903 1.9 0.2–16.3 0.558
 IV             
B symptom          
  Absent 0.4 0.2-1.0 0.057 0.5 0.2-1.0 0.062 0.5 0.2–1.4 0.180 0.5 0.2–1.4 0.187
 Present             
LDH level         
 Normal 0.7 0.3–1.5 0.405 0.9 0.4–1.8 0.693       
Elevated      
Chromosomal abnormality           
 Present 0.9 0.4–2.2 0.869 0.9 0.4–2.1 0.811       
Absent             
Risk stratification          
 L and L-I 0.4 0.2–0.9 0.022 0.4 0.2–0.9 0.020 0.2 0–1.0 0.050 0.2 0–0.7 0.012
 H and H-I             
Breast irradiation         
 Yes 0.4 0.2–0.8 0.008 0.4 0.2–0.8 0.008 0.3 0.1-1.0 0.042 0.3 0.1–0.8 0.021
 No             
Chemical regimen        
 R-DAEPOCH 0.4 0.2–0.9 0.036 0.4 0.2-1.0 0.047 0.1 0-0.5 0.001 0.1 0-0.4 0.001
 R-DAEPOCH/MA 0.3 0.1–0.8 0.013 0.3 0.1–0.9 0.029 0.2 0.1–0.6 0.007 0.3 0.1–0.8 0.018
 R-HyperCVAD             
ASCT
 Yes 0.2 0.1–0.6 0.001 0.2 0.1–0.5 < 0.001 0.1 0–0.4 0.002 0.1 0-0.3 < 0.001
  1. OS overall survival, PFS progression-free survival, HR hazard ratio, 95% CI 95% confidence interval, GCB germinal centre B-cel, LDH lactate dehydrogenase, L low-risk, L-I low-intermediate risk, H high-risk, H-I high-intermediate risk, R-HyperCVAD rituximab, hyperfractionated cyclophosphamide, vincristine, doxorubicin, dexamethasone, alternating with cytarabine plus methotrexate, DA-EPOCH-R rituximab, dose-adjusted etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, DA-EPOCH-R/MA rituximab, dose-adjusted etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, alternating with high-dose methotrexate and cytarabine, ASCT autologous stem cell transplantation
Back to article page

Cancer Cell International

ISSN: 1475-2867

Contact us